http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
연구연속제조업 일정계획 문제에서 기계고장을 고려한 통계적 시뮬레이션 Dispatching 방법 연구
고동진(Dong-Jin Ko),이철웅(Chul-Ung Lee) 한국컴퓨터정보학회 2010 韓國컴퓨터情報學會論文誌 Vol.15 No.8
본 논문에서는 연속제조 생산방식을 취하는 제조업에서 기계고장이 발생하여 생산 일정이 실시간으로 변경되어 야 하는 환경에서도 적용 가능한 dispatching 방법을 개발한다. 개발된 dispatching 방법은 생산지연으로 인한 재료의 재가열 비용과 설치비용, 잔여납기일을 고려하여 지표를 개발하고, 지표의 값이 가장 작은 재료에 우선순위를 부여하여 기계에 할당하는 방식을 취하고 있다. 개발된 dispatching방법의 우수성 입증하기 위해 SPT와 선입선출 방법을 비교대상으로 선출하고, 이들 방법을 통계적 시뮬레이션을 통해 도출된 손실비용을 비교분석한다. 통계적으로 유효성을 입증하기 위해 각 방법별로 200개의 데이터와 20번의 반복을 통해 실험을 실시하며, 실험결과 본 연구에서 제시한 방법이 비교대상 방법에 비해 유효한 손실비용의 감소효과를 보였다. 또한 본 논문에서 개발된 통계적 시뮬레이터는 대기시간에 발생 가능한 비용을 추가하거나 변경이 용이하여 불확실성을 고려한 생산일정계획부문에 유용하게 사용될 것으로 기대한다. We develop a dispatching policy for stochastic scheduling simulation especially for a continuous manufacturing system with machine breakdowns. The proposed dispatching policy computes an urgency index with the consideration of re-heating, setup cost and remaining due date. Prioritized by the index, we execute swapping or reassigning material sequences so as to minimize the total penalty cost. To evaluate the performance of the proposed policy, a discrete event simulation is developed. With 200 data sets and 20 iterations, we compare the performance of the urgency policy with those of SPT (Shortest Processing Time) and FCFS (First Come First Serve) which are the most common policies. The result shows that the proposed policy consistently gives the lowest total costs by reducing the penalty costs for lateness.
이상진 ( Sang Jin Lee ),양지애 ( Ji Ae Yang ),박준원 ( Jun Won Park ),고동진 ( Dong Jin Ko ),권현미 ( Hyun Mi Kwon ),문진영 ( Jin Young Moon ),김영기 ( Young Ki Kim ),최영훈 ( Young Hoon Choi ),이은영 ( Eun Young Lee ) 대한류마티스학회 2014 대한류마티스학회지 Vol.21 No.3
저자들은 국내에서 처음으로 재발다발연골염에 생물학적 제제 사용으로 호전된 바 있는 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Relapsing polychondritis is an episodic, systemic inflammation of the cartilage with unknown autoimmune etiology. It leads to the destruction of cartilaginous structures of the ear, eye, nose, respiratory tract, joints, skin, and heart valve, and its presented symptoms are diverse. It can be improved mainly by corticosteroid or immunosuppressive agents. Recently, the use of biologic agents (TNF inhibitors, rituximab, tocilizumab et al) was reported from abroad. However, there is no reported case of relapsing polychondritis, which is treated by biologic agents in Korea. We report this first case of refractory relapsing polychondritis, which was improved with a treatment of Infliximab.
불응성 염증성 근병증 환자에 대한 Rituximab 치료
양지애 ( Ji Ae Yang ),이상진 ( Sang Jin Lee ),박준원 ( Jun Won Park ),권현미 ( Hyun Mi Kwon ),문진영 ( Jin Young Moon ),고동진 ( Dong Jin Ko ),장성혜 ( Sung Hae Chang ),박진균 ( Jin Kyun Park ),이은봉 ( Eun Bong Lee ),송영욱 ( Yeo 대한류마티스학회 2013 대한류마티스학회지 Vol.20 No.5
Objective. To assess the efficacy and safety of rituximab (RTX) on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy. Methods. Four inflammatory myopathy patients who had been refractory to glucocorticoids, one or more immunosuppressive therapies and intravenous immunoglobulin were treated on an open-label basis. Each patient received two 500 mg doses of RTX 2 weeks apart in one cycle. In one patient who did not respond after the first cycle of RTX, the infusion schedule was modified by the physician. We measured muscle enzyme including CPK, LDH and assessed muscle strength individually to evaluate RTX response. Additionally anti-CD19 antibody was measured. Results. Three patients responded to the first cycle of RTX treatment with improvements in muscle enzyme and muscle strength, and then maintained physical function over the duration of several infusion cycles. In one patient, muscle enzyme did not decrease after the first cycle of RTX, and a high dose glucocorticoid was given. After modifying the treatment schedule with monthly RTX infusion, his muscle enzyme level and muscle strength improved. Anti-CD19 antibody decreased after RTX generally, but responses were variable. Herpes zoster infection occurred in two patients. Conclusion. Rituximab may be a therapeutic choice in refractory inflammatory myopathy. However a further trial is needed to confirm the efficacy and prove the safety.